Approximately 10% to 15% of patients with newly diagnosed prostate cancer have high-risk disease, and up to 50% of this population treated with current standard of care, that is, either radiation therapy (RT) with androgen deprivation therapy (ADT) or radical prostatectomy (RP) with or without planned adjuvant therapy, are at risk for death as a result of the disease.Poorer outcomes are reflected in the failure of these therapeutic approaches to control both local and systemic disease. In medical oncology, the use of chemotherapy in early-stage disease to prevent recurrence and to control both local and systemic disease has been investigated and implemented for decades. The earliest adjuvant therapies for breast cancer that showed benefits were published in 1968. Since then, adjuvant chemotherapy became the standard of care in breast, colon, lung, and other cancers.
Source: Journal of Clinical Oncology
